

Myasthenia Gravis Disease Treatment Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/MAAA1922DC4EEN.html>

Date: March 2022

Pages: 63

Price: US\$ 3,250.00 (Single User License)

ID: MAAA1922DC4EEN

Abstracts

Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.

This report contains market size and forecasts of Myasthenia Gravis Disease Treatment in Global, including the following market information:

Global Myasthenia Gravis Disease Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Myasthenia Gravis Disease Treatment market was valued at 1431.5 million in 2021 and is projected to reach US\$ 2051.2 million by 2028, at a CAGR of 5.3% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Medication Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Myasthenia Gravis Disease Treatment include

GlaxoSmithKline, Novartis, Teva Pharmaceutical, Roche, Bristol-Myers Squibb, Apotex, Cipla, Biogen and AbbVie, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Myasthenia Gravis Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Myasthenia Gravis Disease Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Myasthenia Gravis Disease Treatment Market Segment Percentages, by Type, 2021 (%)

Medication

Surgery

Others

Global Myasthenia Gravis Disease Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Myasthenia Gravis Disease Treatment Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Others

Global Myasthenia Gravis Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Myasthenia Gravis Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Myasthenia Gravis Disease Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Myasthenia Gravis Disease Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

GlaxoSmithKline

Novartis

Teva Pharmaceutical

Roche

Bristol-Myers Squibb

Apotex

Cipla

Biogen

AbbVie

Bausch Health Companies Inc.

Sun Pharmaceuticals

Fresenius Kabi

Piramal Healthcare

RPG Life Sciences

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Myasthenia Gravis Disease Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Myasthenia Gravis Disease Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL MYASTHENIA GRAVIS DISEASE TREATMENT OVERALL MARKET SIZE

- 2.1 Global Myasthenia Gravis Disease Treatment Market Size: 2021 VS 2028
- 2.2 Global Myasthenia Gravis Disease Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Myasthenia Gravis Disease Treatment Players in Global Market
- 3.2 Top Global Myasthenia Gravis Disease Treatment Companies Ranked by Revenue
- 3.3 Global Myasthenia Gravis Disease Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Myasthenia Gravis Disease Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Myasthenia Gravis Disease Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Myasthenia Gravis Disease Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 Myasthenia Gravis Disease Treatment Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Myasthenia Gravis Disease Treatment

Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Myasthenia Gravis Disease Treatment Market Size Markets, 2021 & 2028

4.1.2 Medication

4.1.3 Surgery

4.1.4 Others

4.2 By Type - Global Myasthenia Gravis Disease Treatment Revenue & Forecasts

4.2.1 By Type - Global Myasthenia Gravis Disease Treatment Revenue, 2017-2022

4.2.2 By Type - Global Myasthenia Gravis Disease Treatment Revenue, 2023-2028

4.2.3 By Type - Global Myasthenia Gravis Disease Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Myasthenia Gravis Disease Treatment Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinics

5.1.4 Others

5.2 By Application - Global Myasthenia Gravis Disease Treatment Revenue & Forecasts

5.2.1 By Application - Global Myasthenia Gravis Disease Treatment Revenue, 2017-2022

5.2.2 By Application - Global Myasthenia Gravis Disease Treatment Revenue, 2023-2028

5.2.3 By Application - Global Myasthenia Gravis Disease Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Myasthenia Gravis Disease Treatment Market Size, 2021 & 2028

6.2 By Region - Global Myasthenia Gravis Disease Treatment Revenue & Forecasts

6.2.1 By Region - Global Myasthenia Gravis Disease Treatment Revenue, 2017-2022

6.2.2 By Region - Global Myasthenia Gravis Disease Treatment Revenue, 2023-2028

6.2.3 By Region - Global Myasthenia Gravis Disease Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Myasthenia Gravis Disease Treatment Revenue, 2017-2028

6.3.2 US Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.3.3 Canada Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.3.4 Mexico Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Myasthenia Gravis Disease Treatment Revenue, 2017-2028

6.4.2 Germany Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.4.3 France Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.4.4 U.K. Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.4.5 Italy Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.4.6 Russia Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.4.8 Benelux Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Myasthenia Gravis Disease Treatment Revenue, 2017-2028

6.5.2 China Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.5.3 Japan Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.5.4 South Korea Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.5.6 India Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Myasthenia Gravis Disease Treatment Revenue, 2017-2028

6.6.2 Brazil Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.6.3 Argentina Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Myasthenia Gravis Disease Treatment Revenue, 2017-2028

6.7.2 Turkey Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.7.3 Israel Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.7.4 Saudi Arabia Myasthenia Gravis Disease Treatment Market Size, 2017-2028

6.7.5 UAE Myasthenia Gravis Disease Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 GlaxoSmithKline

7.1.1 GlaxoSmithKline Corporate Summary

7.1.2 GlaxoSmithKline Business Overview

7.1.3 GlaxoSmithKline Myasthenia Gravis Disease Treatment Major Product Offerings

7.1.4 GlaxoSmithKline Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)

7.1.5 GlaxoSmithKline Key News

7.2 Novartis

7.2.1 Novartis Corporate Summary

7.2.2 Novartis Business Overview

7.2.3 Novartis Myasthenia Gravis Disease Treatment Major Product Offerings

7.2.4 Novartis Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)

7.2.5 Novartis Key News

7.3 Teva Pharmaceutical

7.3.1 Teva Pharmaceutical Corporate Summary

7.3.2 Teva Pharmaceutical Business Overview

7.3.3 Teva Pharmaceutical Myasthenia Gravis Disease Treatment Major Product Offerings

7.3.4 Teva Pharmaceutical Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)

7.3.5 Teva Pharmaceutical Key News

7.4 Roche

7.4.1 Roche Corporate Summary

7.4.2 Roche Business Overview

7.4.3 Roche Myasthenia Gravis Disease Treatment Major Product Offerings

7.4.4 Roche Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)

7.4.5 Roche Key News

7.5 Bristol-Myers Squibb

7.5.1 Bristol-Myers Squibb Corporate Summary

7.5.2 Bristol-Myers Squibb Business Overview

7.5.3 Bristol-Myers Squibb Myasthenia Gravis Disease Treatment Major Product Offerings

7.5.4 Bristol-Myers Squibb Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)

7.5.5 Bristol-Myers Squibb Key News

7.6 Apotex

- 7.6.1 Apotex Corporate Summary
- 7.6.2 Apotex Business Overview
- 7.6.3 Apotex Myasthenia Gravis Disease Treatment Major Product Offerings
- 7.6.4 Apotex Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)
- 7.6.5 Apotex Key News
- 7.7 Cipla
 - 7.7.1 Cipla Corporate Summary
 - 7.7.2 Cipla Business Overview
 - 7.7.3 Cipla Myasthenia Gravis Disease Treatment Major Product Offerings
 - 7.7.4 Cipla Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)
 - 7.7.5 Cipla Key News
- 7.8 Biogen
 - 7.8.1 Biogen Corporate Summary
 - 7.8.2 Biogen Business Overview
 - 7.8.3 Biogen Myasthenia Gravis Disease Treatment Major Product Offerings
 - 7.8.4 Biogen Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)
 - 7.8.5 Biogen Key News
- 7.9 AbbVie
 - 7.9.1 AbbVie Corporate Summary
 - 7.9.2 AbbVie Business Overview
 - 7.9.3 AbbVie Myasthenia Gravis Disease Treatment Major Product Offerings
 - 7.9.4 AbbVie Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)
 - 7.9.5 AbbVie Key News
- 7.10 Bausch Health Companies Inc.
 - 7.10.1 Bausch Health Companies Inc. Corporate Summary
 - 7.10.2 Bausch Health Companies Inc. Business Overview
 - 7.10.3 Bausch Health Companies Inc. Myasthenia Gravis Disease Treatment Major Product Offerings
 - 7.10.4 Bausch Health Companies Inc. Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)
 - 7.10.5 Bausch Health Companies Inc. Key News
- 7.11 Sun Pharmaceuticals
 - 7.11.1 Sun Pharmaceuticals Corporate Summary
 - 7.11.2 Sun Pharmaceuticals Business Overview
 - 7.11.3 Sun Pharmaceuticals Myasthenia Gravis Disease Treatment Major Product

Offerings

7.11.4 Sun Pharmaceuticals Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)

7.11.5 Sun Pharmaceuticals Key News

7.12 Fresenius Kabi

7.12.1 Fresenius Kabi Corporate Summary

7.12.2 Fresenius Kabi Business Overview

7.12.3 Fresenius Kabi Myasthenia Gravis Disease Treatment Major Product Offerings

7.12.4 Fresenius Kabi Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)

7.12.5 Fresenius Kabi Key News

7.13 Piramal Healthcare

7.13.1 Piramal Healthcare Corporate Summary

7.13.2 Piramal Healthcare Business Overview

7.13.3 Piramal Healthcare Myasthenia Gravis Disease Treatment Major Product Offerings

7.13.4 Piramal Healthcare Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)

7.13.5 Piramal Healthcare Key News

7.14 RPG Life Sciences

7.14.1 RPG Life Sciences Corporate Summary

7.14.2 RPG Life Sciences Business Overview

7.14.3 RPG Life Sciences Myasthenia Gravis Disease Treatment Major Product Offerings

7.14.4 RPG Life Sciences Myasthenia Gravis Disease Treatment Revenue in Global Market (2017-2022)

7.14.5 RPG Life Sciences Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Myasthenia Gravis Disease Treatment Market Opportunities & Trends in Global Market

Table 2. Myasthenia Gravis Disease Treatment Market Drivers in Global Market

Table 3. Myasthenia Gravis Disease Treatment Market Restraints in Global Market

Table 4. Key Players of Myasthenia Gravis Disease Treatment in Global Market

Table 5. Top Myasthenia Gravis Disease Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Myasthenia Gravis Disease Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Myasthenia Gravis Disease Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Myasthenia Gravis Disease Treatment Product Type

Table 9. List of Global Tier 1 Myasthenia Gravis Disease Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Myasthenia Gravis Disease Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Myasthenia Gravis Disease Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Myasthenia Gravis Disease Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Myasthenia Gravis Disease Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Myasthenia Gravis Disease Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Myasthenia Gravis Disease Treatment Revenue,

(US\$, Mn), 2017-2022

Table 21. By Country - North America Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. GlaxoSmithKline Corporate Summary

Table 31. GlaxoSmithKline Myasthenia Gravis Disease Treatment Product Offerings

Table 32. GlaxoSmithKline Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Novartis Corporate Summary

Table 34. Novartis Myasthenia Gravis Disease Treatment Product Offerings

Table 35. Novartis Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Teva Pharmaceutical Corporate Summary

Table 37. Teva Pharmaceutical Myasthenia Gravis Disease Treatment Product Offerings

Table 38. Teva Pharmaceutical Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Roche Corporate Summary

Table 40. Roche Myasthenia Gravis Disease Treatment Product Offerings

Table 41. Roche Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Bristol-Myers Squibb Corporate Summary

Table 43. Bristol-Myers Squibb Myasthenia Gravis Disease Treatment Product Offerings

Table 44. Bristol-Myers Squibb Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Apotex Corporate Summary

Table 46. Apotex Myasthenia Gravis Disease Treatment Product Offerings

Table 47. Apotex Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Cipla Corporate Summary

Table 49. Cipla Myasthenia Gravis Disease Treatment Product Offerings

Table 50. Cipla Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Biogen Corporate Summary

Table 52. Biogen Myasthenia Gravis Disease Treatment Product Offerings

Table 53. Biogen Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. AbbVie Corporate Summary

Table 55. AbbVie Myasthenia Gravis Disease Treatment Product Offerings

Table 56. AbbVie Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 57. Bausch Health Companies Inc. Corporate Summary

Table 58. Bausch Health Companies Inc. Myasthenia Gravis Disease Treatment Product Offerings

Table 59. Bausch Health Companies Inc. Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 60. Sun Pharmaceuticals Corporate Summary

Table 61. Sun Pharmaceuticals Myasthenia Gravis Disease Treatment Product Offerings

Table 62. Sun Pharmaceuticals Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 63. Fresenius Kabi Corporate Summary

Table 64. Fresenius Kabi Myasthenia Gravis Disease Treatment Product Offerings

Table 65. Fresenius Kabi Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 66. Piramal Healthcare Corporate Summary

Table 67. Piramal Healthcare Myasthenia Gravis Disease Treatment Product Offerings

Table 68. Piramal Healthcare Myasthenia Gravis Disease Treatment Revenue (US\$, Mn), (2017-2022)

Table 69. RPG Life Sciences Corporate Summary

Table 70. RPG Life Sciences Myasthenia Gravis Disease Treatment Product Offerings

Table 71. RPG Life Sciences Myasthenia Gravis Disease Treatment Revenue (US\$,

Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Myasthenia Gravis Disease Treatment Segment by Type in 2021
- Figure 2. Myasthenia Gravis Disease Treatment Segment by Application in 2021
- Figure 3. Global Myasthenia Gravis Disease Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Myasthenia Gravis Disease Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Myasthenia Gravis Disease Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Myasthenia Gravis Disease Treatment Revenue in 2021
- Figure 8. By Type - Global Myasthenia Gravis Disease Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Myasthenia Gravis Disease Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Myasthenia Gravis Disease Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Myasthenia Gravis Disease Treatment Revenue Market Share, 2017-2028
- Figure 12. US Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Myasthenia Gravis Disease Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn),

2017-2028

Figure 23. By Region - Asia Myasthenia Gravis Disease Treatment Revenue Market Share, 2017-2028

Figure 24. China Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Myasthenia Gravis Disease Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Myasthenia Gravis Disease Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Myasthenia Gravis Disease Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. GlaxoSmithKline Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Novartis Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Teva Pharmaceutical Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Roche Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Bristol-Myers Squibb Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Apotex Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Cipla Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Biogen Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. AbbVie Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Bausch Health Companies Inc. Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Sun Pharmaceuticals Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Fresenius Kabi Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Piramal Healthcare Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. RPG Life Sciences Myasthenia Gravis Disease Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Myasthenia Gravis Disease Treatment Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/MAAA1922DC4EEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MAAA1922DC4EEN.html>